ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Esophageal Cancer

Esophageal Cancer

Ahead of the 2017 ASCO Gastrointestinal Cancer Symposium in San Francisco, we spoke with Dr. Geoffrey Ku on the advances in systemic therapy for esophageal and gastric cancer.

Using PET scans during induction chemotherapy for esophageal cancer, researchers were able to assess patient response to treatment and adjust their therapy, leading to an improved rate of pathologic complete response prior to surgery.

Results of a new Swedish study have shown that a surgeon needed to perform at least 15 esophagectomies in cancer patients in order to achieve stable survival results in the first months after the operation.

The addition of lapatinib to capecitabine/oxaliplatin did not prolong overall survival among patients with previously untreated HER2-amplified gastroesophageal adenocarcinoma.

This comprehensive guide for oncologists covers the diagnosis, staging, treatment, and management of esophageal cancer.

Long-term results of the CROSS study have confirmed that neoadjuvant chemoradiotherapy added to surgery should be the standard of care in esophageal or esophagogastric junction carcinoma.

A retrospective analysis found that high expression levels of two angiogenic factors were associated with poor prognosis in esophageal cancer.

Pages

Subscribe to Esophageal Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.